PLC Systems of Franklin, MA, has received approval from the Centro Cardiologico Monzino (CCM-University of Milan) of Milan, Italy, for a randomized clinical trial to evaluate the use of its RenalGuard product.
RenalGuard is an automated, real-time, matched fluid replacement device for interventional cardiology and radiology patients undergoing imaging procedures using contrast media. It is designed to prevent contrast-induced nephropathy (CIN) in high-risk patients undergoing catheterization procedures.
The objective of the clinical trial will be to assess the potential benefits of induced diuresis with matched hydration therapy, compared to standard overnight hydration, in the prevention of CIN in patients undergoing cardiac catheterization procedures and percutaneous coronary interventions with baseline impairment in renal function.
Researchers in the study will use RenalGuard to provide CIN-prevention therapy of induced diuresis and matched hydration therapy.
Related Reading
PLC Systems inks Italian distribution pact, March 28, 2008
PLC to enroll patients in CIN study, March 21, 2008
PLC Systems unveils CIN prevention technology, September 15, 2006
Copyright © 2008 AuntMinnie.com
![Overview of the study design. (A) The fully automated deep learning framework was developed to estimate body composition (BC) (defined as subcutaneous adipose tissue [SAT] in liters; visceral adipose tissue [VAT] in liters; skeletal muscle [SM] in liters; SM fat fraction [SMFF] as a percentage; and intramuscular adipose tissue [IMAT] in deciliters) from MRI. The fully automated framework comprised one model (model 1) to quantify different BC measures (SAT, VAT, SM, SMFF, and IMAT) as three-dimensional (3D) measures from whole-body MRI scans. The second model (model 2) was trained to identify standardized anatomic landmarks along the craniocaudal body axis (z coordinate field), which allowed for subdividing the whole-body measures into different subregions typically examined on clinical routine MRI scans (chest, abdomen, and pelvis). (B) BC was quantified from whole-body MRI in over 66,000 individuals from two large population-based cohort studies, the UK Biobank (UKB) (36,317 individuals) and the German National Cohort (NAKO) (30,291 individuals). Bar graphs show age distribution by sex and cohort. BMI = body mass index. (C) After the performance assessment of the fully automated framework, the change in BC measures, distributions, and profiles across age decades were investigated. Age-, sex-, and height-adjusted body composition reference curves were calculated and made publicly available in a web-based z-score calculator (https://circ-ml.github.io).](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/05/body-comp.XgAjTfPj1W.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
